Induction of multiple CD8+ T cell responses against the inducible Hsp70 employing an Hsp70 oligoepitope peptide

Oncology Reports

Volumn 17, Issue 3, 2007, Pages 679-685

  Faure, Olivier ^a,b,d   Graff Dubois, Stéphanie ^a   Alves, Pedro M S ^a   Cornet, Sébastien ^a   Duffour, Marie Thér̀ese ^b   Scardino, Antonio ^a   Gross, David Alexandre ^a   Miconnet, Isabelle ^a   Salcedo, Margarita ^b   Chouaib, Salem ^a   Lemonnier, François A ^c   Abastado, Jean Pierre ^b   Kosmatopoulos, Kostas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Immuno Designed Molecules   (France)

^c INSTITUT PASTEUR   (France)

^d IDM   (United States)

Author keywords

CTL; Epitopes; Peptides; Tumour immunity; Vaccination

Indexed keywords

EPITOPE; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; GENETIC TRANSFECTION; HUMAN; IMMUNOLOGY; MOUSE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; COS CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, TRANSGENIC; PEPTIDES; TRANSFECTION;

EID: 34247890016     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.3.679     Document Type: Article

References (35)

1. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43, 1999.
2. Kontogeorgos G, Stefaneanu L and Kovacs K: Stress-response proteins in human pituitary adenomas. Expression of heat-shock protein 72 (HSP-72). Endocrine 6: 25-29, 1997. (Pubitemid 27211793)
3. Lazaris AC, Theodoropoulos GE, Davaris PS, Panoussopoulos D, Nakopoulou L, Kittas C and Golematis BC: Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer. Dis Colon Rectum 38: 739-745, 1995.
4. Lazaris A, Chatzigianni EB, Panoussopoulos D, Tzimas GN, Davaris PS and Golematis B: Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 43: 43-51, 1997. (Pubitemid 27090866)
5. Nanbu K, Konishi I, Komatsu T, Mandai M, Yamamoto S, Kuroda H, Koshiyama M and Mori T: Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression. Cancer 77: 330-338, 1996. (Pubitemid 26023352)
6. Nanbu K, Konishi I, Mandai M, Kuroda H, Hamid AA, Komatsu T and Mori T: Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 22: 549-555, 1998. (Pubitemid 28537438)
7. Park CS, Joo IS, Song SY, Kim DS, Bae DS and Lee JH: An immunohistochemical analysis of heat shock protein 70, p53, and estrogen receptor status in carcinoma of the uterine cervix. Gynecol Oncol 74: 53-60, 1999.
8. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R and Dirnhofer S: Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Hum Pathol 29: 1050-1055, 1998. (Pubitemid 28467522)
9. Volm M, Mattern J and Stammler G: Up-regulation of heat shock protein 70 in adenocarcinomas of the lung in smokers. Anticancer Res 15: 2607-2609, 1995. (Pubitemid 26095069)
10. Volm M, Koomagi R, Mattern J and Stammler G: Heat shock (hsp70) and resistance proteins in non-small cell lung carcinomas. Cancer Lett 95: 195-200, 1995.
11. Nylandsted J, Brand K and Jaattela M: Heat shock protein 70 is required for the survival of cancer cells. Ann NY Acad Sci 926: 122-125, 2000. (Pubitemid 32050149)
12. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F and Jaattela M: Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 97: 7871-7876, 2000. (Pubitemid 30460740)
13. Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jaattela M, Penninger JM, Garrido C and Kroemer G: Heat-shock protein 70 antagonizes apoptosisinducing factor. Nat Cell Biol 3: 839-843, 2001. (Pubitemid 32842690)
14. Faure O, Graff-Dubois S, Bretaudeau L, Derre L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP and Kosmatopoulos K: Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int J Cancer 108: 863-870, 2004. (Pubitemid 38112615)
15. Slingluff CL Jr, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP and Ross WG: Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 7: 3012-3024, 2001. (Pubitemid 32963818)
16. Dudley ME, Nishimura MI, Holt AK and Rosenberg SA: Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 22: 288-298, 1999. (Pubitemid 29309961)
17. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN and Chapman PB: T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8: 967-972, 2002. (Pubitemid 34517629)
18. Monsurro V, Nagorsen D, Wang E, Provenzano M, Dudley ME, Rosenberg SA and Marincola FM: Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 168: 5933-5942, 2002. (Pubitemid 34556184)
19. Nielsen MB, Monsurro V, Migueles SA, Wang E, Perez-Diez A, Lee KH, Kammula U, Rosenberg SA and Marincola FM: Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 165: 2287-2296, 2000. (Pubitemid 30648753)
20. Pass HA, Schwarz SL, Wunderlich JR and Rosenberg SA: Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 4: 316-323, 1998.
21. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R and Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-6458, 2001. (Pubitemid 32783251)
22. Knutson KL, Schiffman K and Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484, 2001. (Pubitemid 32167994)
23. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL and Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20: 2624-2632, 2002. (Pubitemid 34575634)
24. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, Vergnon I, Cordopatis P and Kosmatopoulos K: Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J Immunol 157: 3039-3045, 1996. (Pubitemid 126450063)
25. Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G and Cusi MG: 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 97: 1437-1445, 2005. (Pubitemid 41520079)
26. Wang B, Norbury CC, Greenwood R, Bennink JR, Yewdell JW and Frelinger JA: Multiple paths for activation of naive CD8+ T cells: CD4-independent help. J Immunol 167: 1283-1289, 2001. (Pubitemid 32703123)
27. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH and Melief CJ: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-358, 2002. (Pubitemid 34686155)
28. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA and Perarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043-2051, 1997. (Pubitemid 27265987)
29. Michels AA, Kanon B, Konings AW, Ohtsuka K, Bensaude O and Kampinga HH: Hsp70 and Hsp40 chaperone activities in the cytoplasm and the nucleus of mammalian cells. J Biol Chem 272: 33283-33289, 1997. (Pubitemid 28023677)
30. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA and Kosmatopoulos K: A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30: 3411-3421, 2000. (Pubitemid 32005212)
31. Espevik T and Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95: 99-105, 1986. (Pubitemid 17196641)
32. Goxe B, Latour N, Chokri M, Abastado JP and Salcedo M: Simplified method to generate large quantities of dendritic cells suitable for clinical applications. Immunol Invest 29: 319-336, 2000. (Pubitemid 30618025)
33. Gett AV, Sallusto F, Lanzavecchia A and Geginat J: T cell fitness determined by signal strength. Nat Immunol 4: 355-360, 2003. (Pubitemid 36432318)
34. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A and Rocha B: Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 1: 47-53, 2000.
35. Wang RF and Wang HY: Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol 20: 149-154, 2002. Médicale